Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/10010
Title: | Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials | Authors: | BUYSE, Marc | Issue Date: | 2009 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | CANCER JOURNAL, 15(5). p. 421-425 | Abstract: | This article discusses statistical approaches to the validation of surrogate biomarkers and endpoints. One approach that has been successfully used in oncology consists of estimating associations at two levels: the association between the surrogate and the clinical endpoint, called the individual-level association, and the association between the effects of treatment on the surrogate and the clinical endpoint, called the trial-level association. This approach requires data to be available from multiple randomized trials, such as in a meta-analysis of trials based on individual patient data. The approach is illustrated using randomized trials of first-line treatments for advanced tumors of the colon, breast, ovary, and prostate. Data from several meta-analyses suggest that progression-free survival is an acceptable surrogate in advanced colorectal and ovarian cancer, but not in breast and prostate cancer. | Notes: | [Buyse, Marc] IDDI, B-1340 Louvain, Belgium. [Buyse, Marc] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium. | Keywords: | meta-analysis; surrogate endpoint; biomarker; colorectal cancer; breast cancer; ovarian cancer; prostate cancer | Document URI: | http://hdl.handle.net/1942/10010 | ISSN: | 1528-9117 | e-ISSN: | 1540-336X | ISI #: | 000270918300012 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2010 |
Appears in Collections: | Research publications |
Show full item record
WEB OF SCIENCETM
Citations
38
checked on Sep 29, 2024
Page view(s)
74
checked on May 23, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.